Shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) shot up 10.4% on Tuesday . The stock traded as high as $1.86 and last traded at $1.86. 59,024 shares were traded during mid-day trading, a decline of 99% from the average session volume of 8,670,702 shares. The stock had previously closed at $1.68.
Several research firms have recently weighed in on SRNE. StockNews.com downgraded Sorrento Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 21st. HC Wainwright decreased their price target on Sorrento Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 25th.
The company has a quick ratio of 1.55, a current ratio of 1.62 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average of $1.62 and a two-hundred day moving average of $2.91. The stock has a market capitalization of $797.35 million, a price-to-earnings ratio of -1.67 and a beta of 2.43.
About Sorrento Therapeutics (NASDAQ:SRNE)
Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
- Get a free copy of the StockNews.com research report on Sorrento Therapeutics (SRNE)
- ABM Industries, A Clean Play For Dirty Economic Times
- Should Silver Stocks Be A Part Of Your Portfolio?
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
- Two Defensive Stocks To Get Aggressive With
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.